Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: July 03, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 2385 miles
Duke University Medical Center
Durham,NC

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04197999

Your Hormone Therapy & GMI-1359 in Hormone Positive Metastatic Breast Cancer

A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects Scientific Title

Purpose
To study the safety and effects (good and bad) of the experimental drug GMI-1359 when it is used along with a hormone therapy you are currently receiving and responding to.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+) breast cancer, on a hormone therapy, and not receiving a HER2 targeted therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your current hormone therapy</li> <li class="seamTextUnorderedListItem">GMI-1359, by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GMI-1359 is an experimental therapy that targets two proteins--E-selectin and CXCR4--that help tumors spread to other parts of the body. </li> <li class="seamTextUnorderedListItem">Researchers think using GMI-1359 along with hormone therapy will make the hormone therapy more effective.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04197999' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://glycomimetics.com/pipeline/programs/gmi-1359/' target='_blank'>Drug Company Information Page: GMI-1359</a> </li></ul>
See more